Van beleggers
voor beleggers
Uitgebreid zoeken

Beurscodes, betekenis en hulp bij zoeken

Europa

AEX
Euronext Amsterdam
BRU
Euronext Brussels
PSE
Euronext Paris
LIS
Euronext Lissabon
CHX
CBOE Europe, grote(re) EU aandelen
NAV
Investment Funds (NAV)

Noord-Amerika

NYS
New York Stock Exchange
OTC
CBOE BZX Exchange (US)
TSE
Toronto Stock Exchange

Kunt u een instrument niet vinden?

Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code.

Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze.

Waar vind ik die ISIN code?

Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'.

Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.

desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?
Home  /  Forum  /  BioPharma  /  Dendreon

Ontvang nu dagelijks onze kooptips!

word abonnee

BioPharma« Terug naar discussie overzicht

Dendreon

15 Posts
| Omlaag ↓
  1. [verwijderd] 28 juni 2014 13:04
    ff tussendoor,In de US, hou Dendreon (DNDN) in de gaten staat op uitbreken,U weet wel van het product Provenge,

    PROVENGE® (sipuleucel-T) Is FDA Approved

    PROVENGE is the first and only FDA approved immunotherapy
    for advanced prostate cancer

    ps,er staan een kleine 27% short aandelen uit,als die moeten gaan kopen gaat het heeeellll hard zoals in 2007

    www.blackvoicenews.com/news/news-wire...

    er word in de wandelgangen gesproken van een evt Overname/samenwerking....
  4. [verwijderd] 29 juni 2014 15:47
    Dus je zit er groot in beeldscherm ?

    Denk je niet dat de overnames VS uit Europa komen; belastingtechnisch en omdat bedrijven als Cellectis, Nanobiotix, Genfit, Cardio 3 erg goedkoop zijn gezien de mogelijkheden op MT (dankzij bewezen veiligheid en therapeutische voordelen)..

    Naar mijn bescheiden inzicht heb ik het idee dat de VS erg veel kan leren van Europa op het terrein van de behandeling tegen kanker.
    Ik denk dat de stamcel technologie en nano technologie in Europa (in het bijzonder Frankrijk) veel verder gevorderd zijn dan in de rest van de wereld.
    Ik verwacht tot 2017 een behoorlijke reeks aan overnames in de sector@ Europa van Amerikanen.
  5. [verwijderd] 29 juni 2014 16:04
    Aan de andere kant wat moet je met zo een bedrijf als haar enige middel niet aanslaat
    --

    Ongoing disappointment

    While Johnson and Medivation's treatments have been growing rapidly, Dendreon's Provenge continues to disappoint.

    Provenge, which uses patient's immune system to fight prostate cancer, won FDA approval in April, 2010, but never lived up to expectations. In trials, Provenge increased advanced prostate cancer patients' overall survival by four months.

    But sales of the drug failed to take off and are struggling again this year, forcing Dendreon to lay off a significant portion of its employees, including members of its sales team. Sales of the drug totaled just $68 million in the third quarter, which was below analyst's $75 million projections, and 13% less than a year ago.
    Heading into 2014

    2014 marks an important year for the three companies. But the year could prove most critical for money-losing Dendreon. If Provenge sales stabilize, expense cuts could help the company survive. However, if sales continue to shift away from Provenge to Zytiga and Xtandi, then Dendreon's survival may be in question.

    For Johnson's Zytiga, warding off challenges from Medivation's Xtandi may prove difficult; particularly given Johnson will face off with the drug in more markets. Additionally, if the FDA backs Xtandi in the all-important pre-chemo indication as a second-line treatment, Zytiga may lose share in the United States, too.
  13. [verwijderd] 29 oktober 2014 09:43
    Insider-trading probe focuses on Medicare agency.
    Oct 28, 2014

    The day Medicare officials began discussing whether to set new coverage limits on a costly new prostate-cancer treatment, the official in charge emailed three colleagues to put a “close hold” on the process. That meant: Keep quiet until an announcement later that month.

    Yet by the end of that same day, June 7, 2010, shares of the company that made the treatment, Dendreon Corp. DNDN, +4.95% had plunged 10%. Before long, federal investigators took notice.

    Today, the trading in Dendreon around that time is at the center of one of three federal probes exploring whether employees of the Centers for Medicare and Medicaid Services, the agency that oversees billions in health spending, have leaked news that ended up in the hands of Wall Street traders, according to people with direct knowledge of the investigations.

    A flurry of subpoenas has been issued to policy-research firms, Wall Street traders and government officials, said the people familiar with the investigations. Nearly a dozen CMS officials have been interviewed by authorities, and some have struck agreements that allowed them to speak without their words being used against them, said those familiar with the investigation.

    The Securities and Exchange Commission is pursuing the three overlapping insider-trading investigations involving CMS, according to those people and documents reviewed by The Wall Street Journal. One of the cases involves the Federal Bureau of Investigation. Together they represent one of the broadest investigations into leaks of government information to Wall Street.

    Investigators are looking at whether two policy-research firms and a former CMS official in the business of providing information to investors were the middlemen between the government and investors, according to the people with knowledge of the probes.

    uitkomst......$$$$$$$$
  14. [verwijderd] 10 november 2014 14:24

    Biotech Dendreon files for bankruptcy protection

    Reuters
    17 minutes ago
    Nov 10 (Reuters) - Cancer vaccine maker Dendreon Corp filed for Chapter 11 bankruptcy protection on Monday after its potential blockbuster cancer drug failed to live up to expectations, saddling the company with heavy debt.

    Dendreon's stock was down nearly 62 percent at 36 cents in premarket trading.

    The Seattle-based biotechnology company said it had reached agreements on the terms of a financial restructuring with certain bond holders.

    The restructuring may take the form of a standalone recapitalization, or a sale of the company or its assets, it said.

    Under the agreements, senior noteholders will support a plan of reorganization to convert all 2016 notes to common equity of the reorganized Dendreon.
15 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 870,27 -0,43%
EUR/USD 1,0736 +0,36%
FTSE 100 8.078,86 +0,48%
Germany40^ 17.892,30 -1,09%
Gold spot 2.329,96 +0,60%
NY-Nasdaq Composite 15.712,75 +0,10%

Stijgers

UNILEV...
+5,85%
RENEWI
+4,68%
B&S Gr...
+2,85%
Flow T...
+2,26%
Fugro
+2,09%

Dalers

ADYEN NV
-18,43%
VIVORY...
-8,38%
WDP
-4,93%
Alfen ...
-4,39%
CM.COM
-3,66%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links

Meld u aan voor de dagelijkse Beursupdate

Dagelijks een update van het laatste beursnieuws en beleggingskansen in uw mailbox!